Focus on Asthma Care

Back to articles

Montelukast reduces early efficacy of immunotherapy

KEY POINT

In a small, randomized, double-blind, placebo-controlled trial of children with asthma, montelukast (Singulair—Merck), a leukotriene receptor antagonist, reduced efficacy of allergen-specific immunotherapy (SIT), likely by reducing induction of adaptive regulatory T cells.

SOURCES

Majak P et al. Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma. J Allergy Clin Immunol. 2010;125:1220–7.